Table 2.
Baseline characteristics and clinical outcomes
| VAN (n = 43) | DAP (n = 10) CPT (n = 3) | P value | |
|---|---|---|---|
| Baseline characteristics | |||
| Age, median (range) | 53 (25, 89) | 58 (29, 80) | 0.34 |
| Sex, male, n (%) | 23 (53.5) | 10 (77) | 0.2 |
| Body weight, kg, median (IQR) | 68 (59, 86.3) | 88 (72, 99) | 0.06 |
| Serum creatinine, mg/dL, median, (IQR) | 0.76 (0.57, 1.11) | 1.36 (1.09, 1.91) | 0.03 |
| Intensive care unit, n (%) | 5 (11.6) | 1 (7.7) | 0.99 |
| Source of MRSA BSI, n (%) | |||
| Endocarditis | 12 (27.9) | 4 (30.8) | 0.72 |
| Skin and soft tissue | 10 (23.3) | 3 (23.1) | 0.99 |
| Intra-abdominal | 2 (4.7) | 1 (7.8) | 0.53 |
| Bone-joint | 11 (25.6) | 2 (15.4) | 1.00 |
| Central line | 4 (9.3) | 1 (7.8) | 1.00 |
| Unknown | 4 (9.3) | 2 (15.4) | 0.61 |
| Concomitant antibiotics, n (%) | |||
| Piperacillin–tazobactam | 14 (32.5) | 5 (38.4) | 1.00 |
| Aminoglycoside | 2 (4.7) | 1 (7.8) | 0.55 |
| Cefepime | 10 (25.6) | 3 (23.1) | 1.00 |
| Ceftriaxone | 5 (11.6) | 0 | 0.58 |
| Rifampin | 5 (11.6) | 1 (7.8) | 1.00 |
| Other | 5 (11.6) | 3 (23.1) | 0.37 |
| Days concomitant antibiotics, median (IQR) | 2 (1.5, 3.5) | 2 (1, 3) | 0.26 |
| Clinical outcomes | |||
| Duration of hospitalization (days), median (IQR) | 14 (7, 21.5) | 18 (11, 26) | 0.4 |
| Inpatient DOT (days), median (IQR) | 14 (6.5, 19) | 12 (8, 14) | 0.51 |
| Total DOT, median (IQR) | 30 (15, 43) | 19 (13, 40) | 0.97 |
| AKI development, n (%) | 20 (46.5) | 3 (23.1) | 0.2 |
| Initiation of RRT, n (%) | 7 (16.3) | 0 (0) | 0.18 |
| CPK elevations, n (%) | N/A | 1 (7.8) | N/A |
| Hematologic, n (%)a | 7 (16.3) | 0 (0) | 0.18 |
| MRSA BSI persistence, n (%)b | 6 (13.9) | 0 (0) | 0.31 |
| MRSA BSI recurrence, n (%)c | 11 (25.6) | 1 (7.8) | 0.25 |
| 90-day MRSA readmission, n (%) | 17 (39.5) | 3 (23.1) | 0.99 |
| In-hospital mortality, n (%) | 4 (9.3) | 0 (0) | 0.56 |
| 30-day all-cause mortality, n (%) | 4 (9.3) | 0 (0) | 0.56 |
IQR interquartile range, MRSA methicillin resistant Staphylococcus aureus, BSI blood stream infection, DOT duration of treatment, AKI acute kidney injury, RRT renal replacement therapy, CPK creatinine phosphokinase, N/A not applicable
aHematologic defined as a composite of thrombocytopenia or neutropenia
bMRSA BSI persistence defined as positive blood cultures for ≥ 5 days
cMRSA recurrence defined as positive MRSA blood culture ≥ 48 h after negative blood culture